JP2020513418A - ウイルス感染を管理するためのポリペプチド - Google Patents

ウイルス感染を管理するためのポリペプチド Download PDF

Info

Publication number
JP2020513418A
JP2020513418A JP2019551494A JP2019551494A JP2020513418A JP 2020513418 A JP2020513418 A JP 2020513418A JP 2019551494 A JP2019551494 A JP 2019551494A JP 2019551494 A JP2019551494 A JP 2019551494A JP 2020513418 A JP2020513418 A JP 2020513418A
Authority
JP
Japan
Prior art keywords
amino acid
peptide
seq
polypeptide
yodha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019551494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513418A5 (https=
Inventor
サニル ジョージ
サニル ジョージ
ジョシー ジェイコブ
ジョシー ジェイコブ
デビッド ホルトハウゼン
デビッド ホルトハウゼン
ソン ヒ イ
ソン ヒ イ
ジェシカ シャアトウニー
ジェシカ シャアトウニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of JP2020513418A publication Critical patent/JP2020513418A/ja
Publication of JP2020513418A5 publication Critical patent/JP2020513418A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019551494A 2016-12-13 2017-12-01 ウイルス感染を管理するためのポリペプチド Pending JP2020513418A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662433490P 2016-12-13 2016-12-13
US62/433,490 2016-12-13
US201762466066P 2017-03-02 2017-03-02
US62/466,066 2017-03-02
PCT/US2017/064330 WO2018111580A1 (en) 2016-12-13 2017-12-01 Polypeptides for managing viral infections

Publications (2)

Publication Number Publication Date
JP2020513418A true JP2020513418A (ja) 2020-05-14
JP2020513418A5 JP2020513418A5 (https=) 2021-01-14

Family

ID=62559193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019551494A Pending JP2020513418A (ja) 2016-12-13 2017-12-01 ウイルス感染を管理するためのポリペプチド

Country Status (8)

Country Link
US (2) US10898544B2 (https=)
EP (2) EP3909598A1 (https=)
JP (1) JP2020513418A (https=)
CN (1) CN110325206A (https=)
AU (1) AU2017377993A1 (https=)
CA (1) CA3046927A1 (https=)
MX (1) MX2019006943A (https=)
WO (1) WO2018111580A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6148233B2 (ja) 2011-07-11 2017-06-21 インディ モレキュラー，インコーポレイテッド Ａｋｔ特異的捕捉剤、組成物ならびにその使用および製造方法
CN107624115B (zh) 2015-03-16 2021-10-26 加州理工学院 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
CA3046927A1 (en) 2016-12-13 2018-06-21 Emory University Polypeptides for managing viral infections
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US12201679B2 (en) * 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039857A1 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598520A (en) 1898-02-08 Marker s record for laundrymen
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9604593D0 (sv) * 1996-12-13 1996-12-13 Sbl Vaccin Ab Antimicrobially active polypeptides
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140296137A1 (en) * 2013-04-01 2014-10-02 Los Alamos National Security, Llc Methods and compositions for controlling rotifers
CA3046927A1 (en) 2016-12-13 2018-06-21 Emory University Polypeptides for managing viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039857A1 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof

Also Published As

Publication number Publication date
EP3909598A1 (en) 2021-11-17
EP3554533A1 (en) 2019-10-23
US11666630B2 (en) 2023-06-06
EP3554533A4 (en) 2020-07-15
US20190307840A1 (en) 2019-10-10
CA3046927A1 (en) 2018-06-21
US20210138029A1 (en) 2021-05-13
AU2017377993A1 (en) 2019-07-04
CN110325206A (zh) 2019-10-11
WO2018111580A1 (en) 2018-06-21
MX2019006943A (es) 2019-10-21
US10898544B2 (en) 2021-01-26
EP3554533B1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
US11666630B2 (en) Polypeptides for managing viral infections
CA2651793C (en) Hiv fusion inhibitor peptides with improved biological properties
US10493141B2 (en) Viral RNA segments as immunomodulatory agents and vaccine components
US20150132255A1 (en) Hiv vaccine
CN110402145A (zh) 用于增强免疫应答的信使核糖核酸及其使用方法
JP3510249B2 (ja) Ｃ型肝炎ウイルスに特異的な細胞障害性ｔ細胞を刺激するためのペプチド
WO2015110659A1 (en) Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
US11680086B2 (en) Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof
CN109535232B (zh) 多肽、其制备方法及抑制艾滋病病毒的用途
US20160030518A1 (en) Compositions and methods for inhibiting viral activity
JP2024512766A (ja) 高力価ポリペプチドベースのタンパク質阻害のための方法および組成物
WO2011047340A1 (en) Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220427